The Effectiveness of 3% Topical Tranexamic Acid Compared to 4% Topical Hydroquinone as Therapy of Melasma

Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The goal of this clinical trial is to compare 3% Topical Tranexamic Acid with 4% Topical Hydroquinone as Therapy of Melasma in Patients with Skin Type III-V. The main question\[s\] it aims to answer are: 1. Is there a greater decrease in mMASI score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type III - V? 2. Is there a greater decrease in mexameter score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type III - V? 3. Are there any side effects of topical therapy of 3% tranexamic acid cream on melasma patients with skin types III - V? Participants with melasma diagnostic will apply the tranexamic acid cream and hydroquinone cream on both sides of the face differently. Researchers will compare by measuring the mexameter score and mMasi score to see if there any decrease in both sides of the face.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• Female patients diagnosed with melasma.

• 18-60 years old.

• Fitzpatrick skin type III to V.

• Willing to be a research subject (SP) and sign a consent sheet. research (informed consent).

Locations
Other Locations
Indonesia
Cipto Mangungkusumo Hospital
Jakarta
Time Frame
Start Date: 2023-06-01
Completion Date: 2023-09-30
Participants
Target number of participants: 20
Treatments
Experimental: 3 % Topical Tranexamic Acid
Patients will receive 3% Topical Tranexamic Acid, on half of the face, twice a day for a total duration of 2 months
Experimental: 4 % Topical Hydroquinone
Patients will receive 4% Topical Hydroquinone, on half of the face, twice a day for a total duration of 2 months.
Related Therapeutic Areas
Sponsors
Leads: Indonesia University

This content was sourced from clinicaltrials.gov